Tony Huynh

Tony Huynh

Auto-generated profile, based on publicly available information

Tony Huynh

Hematology Department, Saint Louis Hospital, AP-HP, 75010 Paris, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2020 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MHMyriam Hormi
Myriam Hormi
RBRudy Birsen
Rudy Birsen
MBMaya Belhadj
Maya Belhadj
THTony Huynh
Tony Huynh
LALilia Cantero Aguilar
Lilia Cantero Aguilar
Nicolas ChapuisNicolas Chapuis
Nicolas Chapuis

28 June 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
FLFrédérique Larousserie
Frédérique Larousserie
DKDiakho Kebe
Diakho Kebe
THTony Huynh
Tony Huynh
AAAnne Audebourg
Anne Audebourg
JTJerome Tamburini-Bonnefoy
Jerome Tamburini-Bonnefoy
ODOdile Devergne
Odile Devergne
IL-35 is an immunosuppressive cytokine of the IL-12 family consisting of two subunits, EBV-induced gene 3 (EBI3) and p35. It has been shown to play a pro-tumor role in murine tumor models, and in various types of human cancer such as colorectal, pancreatic, or liver carcinoma, its expression has been associated with a worse clinical outcome. Here, we show by analyzing gene expression data from public databases and by immunohistochemical studies that IL-35 is overexpressed by tumor cells in diffuse-large B-cell lymphoma (DLBCL) compared to another type of mature aggressive B-cell lymphoma, Burkitt lymphoma. However, while high IL-35 expression was significantly associated with a worse overall survival in DLBCL patients treated with chemotherapy only (cyclophosphamide, doxorubicin, vincristine, prednisone, CHOP), no significant correlation between IL-35 expression levels and the patient outcome was observed in DLBCL patients treated with CHOP combined to rituximab (R-CHOP), the current conventional treatment. In addition, we found that an anti-IL-35 antibody, clone 15k8D10, used to assess IL-35 expression by immunohistochemistry in various human tissues including tumors does not recognize IL-35 heterodimer, nor its individual subunits EBI3 and p35, but cross-reacts with human IgG1, indicating that IL-35 expression in human cancers needs to be re-evaluated.

8 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
CVCamille Vaganay
Camille Vaganay
FLFrank Ling
Frank Ling
LKLois M. Kelly
Lois M. Kelly
JCJuliette Charles
Juliette Charles
PMPaul-Arthur Meslin
Paul-Arthur Meslin
APAlexandre Puissant
Alexandre Puissant
Chemotherapy resistance in acute myeloid leukemia (AML) remains a major clinical challenge. Integration of multiomic profiling and in vivo functional genomics revealed splicing dysregulation as a determinant of chemoresistance in AML. We uncovered a network involving the splicing regulator SRRM1 and the CLK1/4 and PAK1 kinase families as vulnerabilities in chemoresistant AML cells. Both kinase families are hyperactivated in chemoresistant cells, promoting SRRM1 phosphorylation and altering its scaffolding function. We also identified a relapse-associated PAK1 variant, c.1429G>T p.(Ala 477 →Ser), that confers chemotherapy resistance. Combined PAK1 and CLK1/4 inhibition recapitulated the splicing changes induced by SRRM1 loss, preferentially targeting chemoresistant AML and enhancing chemotherapy efficacy in cell lines, primary cells, and mouse models. Last, we pinpointed MAP2K5 as a critical downstream effector because missplicing of exons 17 and 18 of MAP2K5 upon SRRM1 depletion sensitized cells to chemotherapy. Our findings highlight a therapeutic strategy to overcome AML relapse by targeting splicing dysregulation.